EXPERT VIEW: Recent Cases Lift Pharma Confidence In India IP Protection
This article was originally published in PharmAsia News
Dr. Jonathan Atkinson, member of the board of HGF Ltd, the UK-based intellectual property law firm, has seen a steady pick-up in confidence in India's intellectual property rights (IPR) regime amid a string of critical judgments concerning Big Pharma over the recent past.
You may also be interested in...
AstraZeneca Bolstering India Play With $90m Investment Plan
AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.
Indian Firms Push For Favorable USTR IPR Review
It’s that time of the year when Indian and US firms lock horns around all things IPR [intellectual property rights] ahead of the USTR’s annual Special 301 report. Indian pharma firms want India off the USTR’s Priority Watch List, while PhRMA says it remains concerned about the challenging policy environment and weak patent enforcement in India.
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.